What is xCures?
Founded in 2018 and based in Oakland, California, xCures is pioneering an AI-driven platform designed to conduct 'Virtual Trials.' This innovative methodology continuously learns from the clinical experiences of all patients across all treatments. The platform's 'Virtual Tumor Board' adaptively plans individual patient treatment regimens to optimize outcomes, while simultaneously coordinating plans across the entire patient population to maximize collective learning and therapeutic advancement.
How much funding has xCures raised?
xCures has raised a total of $12.7M across 1 funding round:
Series A
$12.7M
Series A (2021): $12.7M with participation from Boehringer Ingelheim Venture Fund and Vanedge Capital
Key Investors in xCures
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund invests in pioneering science aimed at redefining care standards and developing new medicines for patients. The fund focuses on first-in-class, disease-modifying therapeutics across various modalities.
Vanedge Capital
Vanedge Capital is an early-stage venture capital fund focusing on empowering visionary technologists in the Hard Tech and AI & Analytics sectors. The firm leverages its deep domain expertise and extensive network to support exceptional entrepreneurs.
What's next for xCures?
The recent major strategic investment signals a pivotal growth phase for xCures, likely enabling the company to scale its AI-based virtual trial platform and expand its reach within the oncology sector. This capital infusion is expected to accelerate the development and deployment of its adaptive treatment planning and population-level learning capabilities, positioning xCures to further disrupt traditional clinical trial methodologies and enhance patient care through data-driven insights.
See full xCures company page
